NASDAQ:EKSO - Ekso Bionics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.91 +0.13 (+7.30 %) (As of 05/20/2019 04:00 PM ET)Previous Close$1.78Today's Range$1.75 - $1.9452-Week Range$1.23 - $3.30Volume344,690 shsAverage Volume369,741 shsMarket Capitalization$122.73 millionP/E RatioN/ADividend YieldN/ABeta1.21 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company's Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Receive EKSO News and Ratings via Email Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry General industrial machinery, Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone510-984-1761Debt Debt-to-Equity Ratio0.68 Current Ratio1.73 Quick Ratio1.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$11.33 million Price / Sales10.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book27.29Profitability EPS (Most Recent Fiscal Year)($0.44) Net Income$-26,990,000.00 Net Margins-206.32% Return on Equity-501.28% Return on Assets-121.91%Miscellaneous Employees77 Outstanding Shares64,256,000Market Cap$122.73 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions What is Ekso Bionics' stock symbol? Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO." When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work? Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings Inc (NASDAQ:EKSO) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.01. The company earned $3.30 million during the quarter, compared to analysts' expectations of $3.86 million. Ekso Bionics had a negative net margin of 206.32% and a negative return on equity of 501.28%. View Ekso Bionics' Earnings History. When is Ekso Bionics' next earnings date? Ekso Bionics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Ekso Bionics. What is the consensus analysts' recommendation for Ekso Bionics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ekso Bionics. Has Ekso Bionics been receiving favorable news coverage? Press coverage about EKSO stock has been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ekso Bionics earned a news impact score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Ekso Bionics' key competitors? Some companies that are related to Ekso Bionics include Antares Pharma (ATRS), Corbus Pharmaceuticals (CRBP), Translate Bio (TBIO), ProQR Therapeutics (PRQR), Sorrento Therapeutics (SRNE), Consort Medical (CSRT), Kaleido Biosciences (KLDO), Theratechnologies (TH), Evolus (EOLS), NextCure (NXTC), Valeritas (VLRX), Milestone Pharmaceuticals (MIST), Avrobio (AVRO), Vital Therapies (VTL) and Albireo Pharma (ALBO). What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include TransEnterix (TRXC), XOMA (XOMA), Infinity Augmented Reality (ALSO), Editas Medicine (EDIT), Opko Health (OPK), Innovative Industrial Properties (IIPR), Argos Therapeutics (ARGSQ), Kratos Defense & Security Solutions (KTOS), Uranium Energy (UEC) and Applied DNA Sciences (APDN). Who are Ekso Bionics' key executives? Ekso Bionics' management team includes the folowing people: Mr. Steven A. Sherman, Exec. Chairman (Age 73)Mr. Jack Peurach, Pres, CEO & Director (Age 53)Mr. John F. Glenn, CFO & Sec. (Age 57)Mr. William Shaw, Chief Commercial Officer (Age 45)Ms. Foon Lim Chwee, Pres of APAC Who are Ekso Bionics' major shareholders? Ekso Bionics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.57%), Northern Trust Corp (0.15%), Morgan Stanley (0.11%), PHH Investments Ltd. (0.08%), BlueCrest Capital Management Ltd (0.07%) and Spark Investment Management LLC (0.05%). Company insiders that own Ekso Bionics stock include Amy Mcbride Wendell, Max Scheder-Bieschin, Russ Angold, Steven Sherman and Thomas Looby. View Institutional Ownership Trends for Ekso Bionics. Which institutional investors are selling Ekso Bionics stock? EKSO stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Ekso Bionics. Which institutional investors are buying Ekso Bionics stock? EKSO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., BlueCrest Capital Management Ltd, Spark Investment Management LLC, Northern Trust Corp, Bailard Inc., Pinnacle Associates Ltd., Charles Schwab Investment Management Inc. and ExodusPoint Capital Management LP. Company insiders that have bought Ekso Bionics stock in the last two years include Amy Mcbride Wendell, Max Scheder-Bieschin, Steven Sherman and Thomas Looby. View Insider Buying and Selling for Ekso Bionics. How do I buy shares of Ekso Bionics? Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ekso Bionics' stock price today? One share of EKSO stock can currently be purchased for approximately $1.91. How big of a company is Ekso Bionics? Ekso Bionics has a market capitalization of $122.73 million and generates $11.33 million in revenue each year. The company earns $-26,990,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe. What is Ekso Bionics' official website? The official website for Ekso Bionics is http://www.eksobionics.com. How can I contact Ekso Bionics? Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected] MarketBeat Community Rating for Ekso Bionics (NASDAQ EKSO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 198 (Vote Underperform)Total Votes: 436MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: How does new data get added to a blockchain? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.